PV-10: Phase Ib/II start

Next month, Provectus will begin an open-label, international Phase Ib/II trial to evaluate intralesional PV-10 every 3 weeks for 15 weeks plus IV Keytruda pembrolizumab every 3 weeks for up to 24 mo...